Diagnosis of early mycosis fungoides (MF) is challenging and often delayed, in part due to the heterogeneity, subtlety, and location of lesions, which may mimic benign inflammatory dermatoses, but also a general lack of physician awareness. |
Early diagnosis of MF is critical to avoid distress for the patient, who may be misdiagnosed and receive unnecessary and potentially harmful treatments, and probably to mitigate the risk of disease progression. |
There is an urgent need for increased physician education regarding MF to enable expedited specialist referrals, and improved tools facilitating a speedy diagnosis, so that patients may receive guideline-recommended treatments early in their patient journey. |
1 Introduction
Stage | T | N | M | B |
---|---|---|---|---|
IA | T1: patches and/or plaques over <10% of BSA T1a: patches only T1b: plaques with or without patches | N0: no clinically enlarged nodes | M0: no visceral involvement | B0: < 250 per μL of CD4+CD26- or CD4+CD7-cells by flow cytometry B1: does not meet criteria for B0 or B2 |
IB | T2: patches and/or plaques over ≥10% of BSA T2a: patches only T2b: plaques with or without patches | N0 | M0 | B0 to 1 |
IIA | T1 or T2 | N1: clinically enlarged nodes but histologically uninvolved (dermatopathic) N1a: clone negative N1b: clone positive N2: early involvement with MF (low level of nodal involvement), aggregates of atypical cells with preservation of nodal architecture N2a: clone negative N2b: clone positive | M0 | B0 to 1 |
IIB | T3: tumors; lesions ≥ 1 cm diameter with deep infiltration | N0 to 2 | M0 | B0 to 1 |
IIIA | T4: erythroderma > 80% BSA involved | N0 to 2 | M0 | B0 |
IIIB | T4: erythroderma | N0 to 2 | M0 | B1 |
IVA1 | T1–T4 | N0 to 2 | M0 | B2: ≥ 1000 per μL of CD4+CD26- or CD4+CD7- cells by flow cytometry in the presence of a relevant T-cell clone in blood (identical to skin clone) |
IVA2 | T1–T4 | N3: lymph nodes involved with loss of normal architecture | M0 | B0 to 2 |
IVB | T1–T4 | N0 to N3 | M1: metastasis | B0 to 2 |
2 Methodology Used for Expert Panel Discussion
2.1 Aim
2.2 Methodology
3 Overview
3.1 Diagnostic Delays
3.2 Steps to Arrive at a Correct Diagnosis
3.2.1 Physical and Histopathological Examination
3.2.2 Recommendations to Increase Biopsy Yield
3.3 Awareness and Training
4 Diagnostic Checklists
Main clinical clues for early MF or MF variant that should raise the red flag |
---|
Persistent and/or progressive erythematous patches/plaques, sometimes with skin atrophy, especially in sanctuary areas |
Persistent and/or progressive hypopigmented or hyperpigmented patches/plaques, sometimes with skin atrophy, especially in sanctuary areas |
Elongated patches/plaques, especially that follow the cleavage lines, or kidney-shaped lesions located along the sides of the trunk and/or inner aspects of the extremities |
‘Non-specific dermatitis’ on non-sanctuary areas that may be associated with pruritus, especially if progressive |
Any unusual atopic dermatitis: |
• Presumed ‘late-onset atopic dermatitis’, especially in the absence of a family/personal history of atopic dermatitis or atopic diathesis during childhood |
• Absence of pruritus |
• Prominent infiltration/induration of lesions on palpation |
• Worsening of an eruption diagnosed as atopic dermatitis during treatment with appropriate therapies: topical agents and systemic treatment |
Any unusual psoriasis vulgaris: |
• Psoriasiform lesions with erosions/ulceration and/or impetiginization |
• Worsening of an eruption diagnosed as psoriasis during treatment with appropriate therapies: topical agents and systemic treatment |
• ‘Psoriatic lesions’ with erosions/ulceration and/or impetiginization |
Any unusual keratoderma palmaris and/or plantaris after excluding the most common causes: |
• Psoriasis, contact dermatitis/atopic dermatitis, and/or tinea |
Any unusual follicular-based rash: |
• Erythematous, hypopigmented and/or hyperpigmented patches/plaques with follicular accentuation |
• Lesions resembling keratosis pilaris but in an unusual distribution and/or in clusters sometimes on faint base |
• Acneiform eruptions in the absence of any relevant drug or known relevant associated condition; comedones in locations not characteristic of acne or hidradenitis suppurativa; acneiform and concomitant eczematous or psoriasiform lesions in the same areas |
• Localized hair loss on what seems to be ‘dermatitis’ or in areas without lesions but only with scales (also look for focal eyebrow loss) |
Any unusual chronic pigmented purpuric dermatosis: |
• Patches/plaques in an extensive distribution (beyond the lower legs, occasionally with the buttocks—the usual locations in most cases) |
• Coexisting with ‘nonspecific dermatitis’ |
Histopathologic features suggestive of early MF | Pitfalls |
---|---|
Epidermis
| |
Pautrier micro-abscesses | Spongiotic Langerhans’ cell vesicles |
Lymphocytic epidermotropism generally without spongiosis | Spongiosis |
Epidermal lymphocytes larger than dermal lymphocytes | |
Tagging (lining up) of lymphocytes at the dermoepidermal junction | Interface or lichenoid dermatitis |
High nuclear variability, hyperchromatic and/or folded nuclei, pericellular halo | Nuclear irregularities seen with interface/lichenoid dermatitis |
Dermis
| |
Superficial dermal band-like lymphoid infiltrate | Lichenoid dermatitis, PPD |
Fibrosis of papillary dermis (sign of chronicity) | Chronic/lichenified dermatitis |
Variant folliculotropic MF: perifollicular lymphocytic infiltrate with folliculotropism with/without follicular mucinosis | Perifollicular infiltrates may be sparse |
Immunopathologic features
a
suggestive of early MF
| |
Increased CD4:CD8 ratio (CD4−, CD8+ or CD4−CD8−) | CD4−CD8− can also be observed after skin-directed (e.g., topical steroid) therapy |
Loss of T-cell–marker expression on CD4+ lymphocytes | BID (drug- and contact-related) associated with loss of pan T-cell markers, particularly CD7 |
5 Discussion
Common themes | Details |
---|---|
Diagnostic delays | Delays are common for all regions |
Clinical diagnostic uncertainty | Given the diagnostic challenges, some clinicians may try various treatments before referral |
Incomplete physical examination | In cases of incomplete dermatologic examination (patients not undressed), physicians may fail to identify key lesions in sun-protected areas |
Histopathology importance | Selecting the correct skin site for biopsy is key for MF to be diagnosed Notes: • Presence of eosinophils could lead to misdiagnosis as a hypersensitivity reaction • Poikilodermatous MF can mimic the interface of lichenoid dermatitis • Ashy dermatosis/lichen planus pigmentosus and other lichenoid dermatoses can mimic MF; often mild lymphoid atypia are noted, requiring ancillary tests • Hypopigmented MF generally has a normal number of junctional melanocytes or only focal loss, unlike vitiligo, which presents with a significant loss of junctional melanocytes • Folliculotropic MF may show only a sparse perifollicular infiltrate or show features of follicular distortion/destruction, mucin deposition and follicular induction • In patients with suspected folliculotropic MF, in whom adnexal structures are barely seen or not seen at all at initial evaluation, deeper sections should be ordered |
Lack of awareness and education on MF | Education on MF is lacking for clinicians and for students in medical school |
Regional differences | Details |
Insurance and reimbursement issues | Access to both specialists and treatments varies from country to country |
Terminology | Parapsoriasis is historically established and used as a diagnosis before MF is certain in many regions, but rarely in the United States |
Staging and testing | Use of point-based staging, blood and lymph node investigation, flow cytometry, and imaging varies across regions |